<DOC>
	<DOCNO>NCT01653483</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , repeat dose , 2-period , incomplete block , crossover , safety pharmacokinetic ( PK ) study evaluate 3 once-daily dos umeclidinium ( GSK573719 ; UMEC ) adolescent asthma subject age 12 17 year , ) currently use asthma medication contain inhaled corticosteroid ( non-ICS ) . The objective investigate safety tolerability , PK 7-day ( +2 ) repeat once-daily dose UMEC ( 15.6 , 62.5 , 250 mcg ) asthmatic adolescent subject . Safety endpoint include reported adverse event , vital sign , ECGs , clinical laboratory test , rescue albuterol use . The PK endpoint include serial PK ( plasma urine ) concentration derive parameter . Twenty four subject randomize participate study 7 week ( include : initial screen visit , 7 14-day run-in , 2 treatment period 7 ( +2 ) day duration , washout period 7-14 day treatment period ) . There Follow-up Visit approximately one week end second treatment period . Subjects refrain use rescue medication 4 hour prior clinic visit , unless emergency . During treatment period , study medication take morning morning Day 7 ( +2 day ) subject return clinic study assessment take last dose study medication . On Day 7 ( +2 ) , subject remain clinic overnight serial assessment ( ECG , PK plasma urine sample 24-hours ) .</brief_summary>
	<brief_title>Aura Adolescent PK Study GSK2829332</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , repeat dose , 2-period , incomplete block , crossover , safety pharmacokinetic ( PK ) study evaluate 3 once-daily dos umeclidinium ( UMEC ) adolescent asthma subject age 12 17 year , ) currently use asthma medication contain inhaled corticosteroid ( non-ICS ) . The objective investigate safety tolerability , PK 7-day ( +2 ) repeat once-daily dose UMEC ( 15.6 , 62.5 , 250 mcg ) asthmatic adolescent subject . Safety endpoint include reported adverse event , vital sign , ECGs , clinical laboratory test , rescue albuterol use . The PK endpoint include serial PK ( plasma urine ) concentration derive parameter .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Demographic Informed consent : At least one parent/guardian sign date write informed consent prior admission study . This accompany informed assent subject child age 12 17 year . Type Subject : Outpatients . However subject remain clinic overnight end treatment period serial safety PK blood urine assessment 24hour period . Age : subject age 12 17 year ( inclusive ) Visit 1 ( subject may participate subject 's 18th birthday would occur conduct study ) . Note : The study population include adequate representation subject throughout age 12 17 year least 4 subject 12 13 year age 4 subject 16 17 year age . Weight : Subjects must weigh least 32kg . Male Eligible Female . Eligible define nonchildbearing potential childbearing potential use acceptable method birth control consistently correctly . Note : To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control , define : Females childbearing potential sexually active must commit complete abstinence intercourse throughout clinical trial period trial account elimination drug ( minimum 6 day ) ; Male partner sterile prior female subject 's entry study sole sexual partner female subject ; Implants levonorgestrel etonogestrel ; Injectable progestogen ; Oral contraceptive ( either combine progestogen alone ) ; Estrogenic vaginal ring ; Percutaneous contraceptive patch ; Any intrauterine device ( IUD ) document failure rate le 1 % per year ; Male condom combine vaginal spermicide ( foam , gel , film , cream , suppository ) ; Male condom combine female diaphragm , either without vaginal spermicide ( foam , gel , film , cream , suppository ) ; Contraceptive transdermal patch , Ortho Evra ( subject less 198 pound [ 90kg ] ) ; Female subject enrol pregnant lactating plan become pregnant time study participation . A serum pregnancy test require female perform initial screen visit ( Visit 1 ) . In addition , urine pregnancy test perform Table Time Events . Understand protocol requirement : The subject parent/guardian able understand comply protocol requirement , instruction , protocol state restriction . The parent guardian must ability read , write , record diary information collect throughout study . The parent guardian must ability manage study drug administration . AsthmaRelated Diagnostic Inclusion Criteria Diagnosis : diagnosis asthma define National Institutes Health [ NIH , 2007 ] least 6 month prior Visit 1 . Severity Disease : A best prebronchodilator AM FEV1 great equal 80 % predict normal value Visit 1 ( screen ) visit . Percent predict normal value base upon : NHANES III ( Hankinson , 1999 ) primary race/ethnicity subject ( e.g MexicanAmerican , AfricanAmerican/African heritage , Caucasian ) ; Multiethnic spirometric assessment ( Hankinson , 2010 ) primary race/ethnicity subject ( e.g Asian ) . Current AntiAsthma Therapy : Subjects must demonstrate need use noncorticosteroid medication show received prescription either follow great equal 12 week precede Visit 1 ( ICS use least 12 week prior screen ) : noncorticosteroid controller ( e.g. , theophylline , cromolyn , nedocromil , leukotriene modifier [ e.g . montelukast , zafirlukast ] , etc . ) , without SABA ; SABA bronchodilator albuterol . ShortActing Beta2Agonists ( SABAs ) : All subject must able replace current SABA treatment albuterol aerosol inhaler Visit 1 , need , duration study . Subjects must judge capable withhold albuterol least 4 hour prior study visit . Demographic Exclusion Criteria Tobacco Use : A subject may use inhale tobacco product ( i.e. , cigarette , cigar , pipe tobacco ) historical use tobacco product . Includes , urinary cotinine CO breath test level screen indicative smoking history regular use tobacco nicotinecontaining product within 6 month prior screen . Previous Use Study Drug Investigational Products : Previous use UMEC exclude subject subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Compliance : A subject eligible he/she his/her parent legal guardian infirmity , disability , disease , geographical location seem likely ( opinion investigator ) impair compliance aspect study protocol , include visit schedule completion daily diary . Alcohol substance abuse : Subjects history alcohol use substance abuse prior screening , use , time study . Viral Hepatitis : A positive Hepatitis B surface antigen positive Hepatitis C antibody prestudy Visit 1 . Wards State : Children ward state government . Affiliation Investigator 's Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Pregnancy : Pregnant female determine positive serum hCG test screen prior dosing . Lactation : Lactating female . AsthmaRelated Exclusion Criteria History Lifethreatening asthma : Defined protocol asthma episode require intubation and/or associate hypercapnea require noninvasive ventilator support , respiratory arrest , hypoxic seizure asthmarelated syncopal episode ( ) . Asthma Exacerbation : A subject must history severe asthma exacerbation within 12 week prior Visit 1 . A severe asthma exacerbation define deterioration asthma require use systemic corticosteroid ( oral , injection ) least 3 day inpatient hospitalization emergency department visit due asthma require systemic corticosteroid . Signs symptom unstable asthma : Defined : During 7 day immediately precede visit , least 3 day great equal 12 inhalations/day albuterol/salbutamol use ; A symptom score great equal 4 least 3 consecutive day previous 7 day ( define subject experience symptom day affect normal daily activity ) ; discretion Investigator Respiratory Infection expect affect subject 's ability participate study : Within 4 week prior Visit 1 subject culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus middle ear resolve led change asthma management , opinion Investigator , expect affect subject 's asthma status subject 's ability participate study . Concurrent Respiratory Disease : A subject must current evidence pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , bronchopulmonary dysplasia , chronic bronchitis , emphysema , chronic obstructive pulmonary disease , respiratory abnormality asthma . Diseases Preventing Use Anticholinergics : Diagnosis narrowangle glaucoma , bladder neck obstruction opinion study investigator GSK medical monitor would pose safety risk use inhale anticholinergic . Other Concurrent Diseases/Abnormalities : A subject must clinically significant , uncontrolled condition disease state , opinion investigator , would put safety patient risk study participation condition/disease exacerbate study . The investigator encourage contact study medical monitor clarification warrant . Safety Exclusion Criteria Liver Function : ALT great equal 2xULN ; alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin le 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Average QTcF great 450 msec . Allergies : Drug Allergy Any adverse reaction include immediate delay hypersensitivity betaagonist , sympathomimetic drug . Known suspected sensitivity constituent NDPI ( i.e. , lactose ) . Previous Clinical Trials : Exposure four new chemical entity within 12 month prior first dose day . Concomitant Medication Treatments : Administration prescription overthecounter medication would significantly affect course asthma , interact study drug , : : Medication : Mucolytics acetylcysteine ; beta blocker eye drop ( e.g . use glaucoma symptom treatment ) systemic betaadrenergic block agent ; No use within follow time interval Visit 1 : 12 week . Medication : Inhaled shortacting beta2agonists ( rescue use albuterol permit study ) ; No use within follow time interval Visit 1 : 4 hour ( include study visit ) . Medication : Short act anticholinergic ; No use within follow time interval Visit 1 : 6 hour . Medication : Long short act oral beta2agonists ; No use within follow time interval Visit 1 : 24 hour . Medication : Long act anticholinergic antimuscarinics ; No use within follow time interval Visit 1 : 14 day . Medication : Systemic , depot , oral corticosteroid ; No use within follow time interval Visit 1 : 4 week . Medication : Inhaled corticosteroid ( ICS ) ; No use within follow time interval Visit 1 : 12 week . Medication : Inhaled longacting beta2agonists ( e.g . salmeterol , formoterol , indacaterol ) include longacting beta2agonists combine ICS ( e.g . Advair , seretide ) ; No use within follow time interval Visit 1 : 4 week . Medication : Immunosuppressive medication ( e.g. , methotrexate , gold , dapsone ) include immunomodulators ( Immunotherapy treatment allergy allow study provide initiate least 4 week prior Visit 1 subject remain maintenance phase throughout study ) ; No use within follow time interval Visit 1 : 12 week . Medication : Monoclonal antibody : AntiIgE , monoclonal antibody , reason ( e.g. , omalizumab ) ; No use within follow time interval Visit 1 : 5 month . Medication : Strong moderate pgp inhibitor ( e.g . dronedarone , ritonavir , indinavir , quinidine , valspodar , elacridar ( GF120918 ) ; No use within follow time interval Visit 1 : 4 week . Medication : Strong moderate CYP2D6 inhibitor ( bupropion , fluoxetine , paroxetine , quinidine , ecstasy , terbinafine , cinacalcet , ritonavir , tipranavir , moclobemide , duloxetine , dronedarone ) ; No use within follow time interval Visit 1 : 4 week . Medication : Any investigational drug ; No use within follow time interval Visit 1 : 30 day within 5 drug halflives investigational drug ( whichever longer ) Liver Disease : Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Bundle branch block : Subjects right leave bundle branch block . Blood Volume : Where participation study would result donation blood blood product excess 500mL within 56day period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Umeclidinium</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>